HALO logo
halo search icon
Cardiff Oncology, Inc.
Cardiff Oncology, Inc.
CRDF · NAS

Cardiff Oncology, Inc.

US$1.84

Price Arrow0.08 (4.54%)
20/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusHALO AllHALO Consensus ValueRecent Earnings downgrade
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Cardiff Oncology, Inc. Overview

CRDF Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Neutral

Earnings

Strong

Growth

Earnings

Neutral

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About CRDF

icon

Telephone

1.858.952.7570

icon

Address

11055 Flintkote Avenue, San Diego, CA 92121

Description

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The firm is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

CRDF Price Chart

Key Stats

Market Cap

US$120.33M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 1.48 - 4.55

Trade Value (12mth)

US$751,311.00

1 week

5.39%

1 month

6.67%

YTD

-33.83%

1 year

-39.31%

All time high

2030.40

Key Fundamentals

EPS 3 yr Growth

-22.70%

EBITDA Margin

NaN%

Operating Cashflow

-$38m

Free Cash Flow Return

-58.70%

ROIC

-70.90%

Interest Coverage

0.00

Quick Ratio

3.70

Other Data

Shares Outstanding (Fully Diluted)

68m

HALO Sector

Healthcare

Next Company Report Date

04-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

CRDF Announcements

Latest Announcements

DateAnnouncements
20 May 26
20 May 26
15 May 26
15 May 26
15 May 26

CRDF Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-0.93-0.95-0.69locklocklock
EPS (Fully Diluted)
$locklocklocklock-0.93-0.95-0.69locklocklock
Growth
%locklocklocklock-4.5-2.828locklocklock
PE
XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Cardiff Oncology, Inc. (CRDF:NAS)?
Halo FAQ
The current share price of Cardiff Oncology, Inc. (CRDF:NAS) is USD$1.84.
What is the 52-week high share price for Cardiff Oncology, Inc. (CRDF:NAS)?
Halo FAQ
The 52-week high share price for Cardiff Oncology, Inc. (CRDF:NAS) is USD$4.55.
What is the 52-week low share price for Cardiff Oncology, Inc. (CRDF:NAS)?
Halo FAQ
The 52-week low share price for Cardiff Oncology, Inc. (CRDF:NAS) is USD$1.48.
What is the dividend yield for Cardiff Oncology, Inc. (CRDF:NAS)?
Halo FAQ
Cardiff Oncology, Inc. (CRDF:NAS) does not pay a dividend.
What was Cardiff Oncology, Inc. (CRDF:NAS) last dividend payment?
Halo FAQ
Cardiff Oncology, Inc. (CRDF:NAS) does not pay a dividend.
What is the franking level for Cardiff Oncology, Inc. (CRDF:NAS)?
Halo FAQ
Cardiff Oncology, Inc. (CRDF:NAS) has a franking level of 0.00%.
In which sector is Cardiff Oncology, Inc. (CRDF:NAS) classified?
Halo FAQ
Cardiff Oncology, Inc. (CRDF:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.